Lindsay Rosenwald in the News
New York Times Article
This New York Times article goes over the appointment of Dr. Lindsay Rosenwald as the director of corporate finance at D. H. Blair & Company’s Wall Street firm at age 33. It talks about his background and decision to become a biotech investor.
It discusses his Penn State background in finance but how he moved on with the thought of becoming a doctor. Even while in school, however, Lindsay Rosenwald continued his work and interest in finance. This was even commented on during his Abington Hospital internship.
It continued to mention how Dr. Lindsay Rosenwald established a private practice for two and a half years prior to coming to Wall Street as a securities analyst at Ladenburg & Thalmann prior to making the move to D. H. Blair & Company (a company specializing in venture capital and public offerings).
He made the shift because he wanted to be able to focus on investments in the health care industry. Lindsay Rosenwald does admit, however, that he sometimes misses his patients, but specifies that the move to Wall Street was definitely what he wanted.
Various mentions are made in this article of Rosenwald’s background that prepared him so effectively for the Biotech industry, and goes into his early moves to and within Wall Street.
Reverse Merger Blog
This August, 2009 article from the reverse merger blog praises the massive reverse merger of Cougar Biotech. The article specifies that the company was sold to Johnson and Johnson via reverse mortgage (using a Form 10 shell) for a total of $1 billion (US).
The article mentions the 2006 Form 10 shell reverse merger of Cougar as a further example of the use of this reverse merger construction. It notes that the stock prices for Cougar have risen a full 145% since the merger was completed, and mentions some additional details of note in the merger.
It cites comments from Lindsay Rosenwald on the
Related posts: